CN102198203B - Traditional Chinese medicine for treating nonalcoholic fatty liver diseases - Google Patents
Traditional Chinese medicine for treating nonalcoholic fatty liver diseases Download PDFInfo
- Publication number
- CN102198203B CN102198203B CN2011101554576A CN201110155457A CN102198203B CN 102198203 B CN102198203 B CN 102198203B CN 2011101554576 A CN2011101554576 A CN 2011101554576A CN 201110155457 A CN201110155457 A CN 201110155457A CN 102198203 B CN102198203 B CN 102198203B
- Authority
- CN
- China
- Prior art keywords
- parts
- fatty liver
- rhizoma
- radix
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine for treating nonalcoholic fatty liver diseases, which has function of eliminating pathogens and strengthening the body resistance, and has no side effects. The traditional Chinese medicine for treating nonalcoholic fatty liver diseases comprises following components in parts by weight: 5 to 20 parts of root of Chinese thorowax, 4 to 12 parts of liquorice, 15 to 45 parts of polygonum cuspidatum, 5 to 10 parts of gensing, 10 to 30 parts of hawthorn, 8 to 16 parts of alisma, 15 to 35 parts of root of red-rooted salvia, 5 to 10 of white atractylodes rhizome, 10 to 30 parts of tuckahoe, 5 to 25 parts of cassia seed, 10 to 35 parts of lotus petiole, and 6 to 12 parts of rhizoma acori graminei. Besides the functions of soothing the liver, relieving pain, invigorating the circulation of blood, nourishing the blood, removing stasis, softening hardness, lowering blood fat, and detoxifying toxic material, the traditional Chinese medicine also has functions of tonifying the stomach and the spleen, reducing phlegn and promoting diuresis on the foundation of f tonifying the stomach and the spleen, promoting the circulation of qi of the stomach, moistening dryness, relieving constipation, reducing phlegm, promoting digestion and removing food retention.
Description
Technical field
The present invention relates to a kind of medicine of treating non-alcohol fatty liver, specifically is the Chinese medicine compound of feedstock production with the Chinese herbal medicine.
Background technology
Fatty liver disease is called for short fatty liver, is meant the pathological changes of fatty overheap in the hepatocyte that causes owing to a variety of causes.The positive serious threat compatriots' of fatty liver disease health becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.Fatty liver disease comprises alcohol fatty liver and non-alcohol fatty liver two big classes.Alcohol fatty liver is because the liver histological that long-term heavy drinking causes changes, and is to be main disease with the hepatic cell fattydegeneration.Non-alcohol fatty liver (nonalcoholic fatty liver disease; NAFLD) be a kind of no excessive history of drinking history; Athero in the stem cell that is caused by a variety of causes is the clinical pathology syndrome of principal character with hepatic cell fattydegeneration and accumulation of lipid.
EPDML research shows; The Along with people's growth in the living standard, rhythm of life is accelerated, and rule of life changes; High protein, absorption higher fatty acid, high-carbonhydrate diet increase; The sickness rate of non-alcohol fatty liver constantly raises in the metabolic hepatopathy in recent years, and age of onset is more and more littler, and non-alcohol fatty liver has become the second largest hepatopathy that is only second to viral hepatitis in certain areas.Obesity, diabetes and alcoholism are the three big causes of disease of fatty liver.And the origin cause of formation regardless of simple fatty liver; Always there is the part patient to develop into fatty liver hepatopathy and hepatic fibrosis; Even cause fatty cirrhosis and relevant disease thereof, and the effectively anti-rule of treatment of fatty liver can stop the progress of chronic hepatopathy and improve its prognosis.
The clinical manifestation of fatty liver is an inappetence, and is weak, detest oil, feel sick, vomiting, and abdominal distention, dull pain in liver, dizzy, sialorrhea, pulse is slow, and blood pressure reductions etc. are at present clinically to the treatment of the non-alcohol fatty liver complete method of none cover still.Doctor trained in Western medicine often adopts simple fat-reducing medicament to handle, and the pathology of non-alcohol fatty liver not merely is the blood fat reducing problem, also comprises behind the intrahepatic fatty infiltration Western medicine blood fat reducing is used in the infringement of liver function merely, tends to have side effects, and has damaged liver function.
Chinese herbal treatment can be used as a kind of alternative medicine treatment non-alcohol fatty liver.The blood fat reducing medicine of selling in the market especially Chinese medicine preparation stresses eliminating evil, the broken silt of removing blood stasis mostly, and ignorance is set upright, the harmonizing the liver and spleen kidney, thereby unsatisfactory curative effect; As taking removing blood stasis to break the silt therapy to the relatively poor severe fatty liver patient of body constitution; Often cause the patient's eyes blackout, the heart is nervous, and lower limb is trembled; Have blood in stool, the state of an illness is controlled heavier and heavier; Next is that side effect is bigger, and " Xuezhikang " produced like Beijing University can cause gastrointestinal upset, and stomach is scorching hot, and flatulence has a stomach-ache, the slight rising of serum transaminase etc.; " fenofibrate capsules " that France produces can cause skin allergy, myalgia, dyspepsia etc.; " Hedan tablet " that Nanchang produces can cause diarrhoea once in a while, feels sick xerostomia; " SHANHAI PILL " that Xi'an produces can make patient's dry mouth and tougue etc.; " simvastatin " that Hangzhou produces can cause tired, unable, and abdomen is painful, feels sick etc.; " Etofylline Clofibrate sheet " that six pharmaceutical factories, Hefei produce can make the patient that feeling of repletion is arranged, and skin is itched, the slight rising of transaminase etc.
Summary of the invention
For overcoming the defective of existing treatment non-alcohol fatty liver medicine; The present invention provides eliminating evil and sets upright the Chinese medicine that develops simultaneously and have no the treatment non-alcohol fatty liver of side effect; Soothing the liverly alleviate pain except having, the nourishing blood and promoting blood circulation, blood stasis dispelling softening the hard mass, blood fat reducing antidotal effect, but the gas of the clear sun of elevate a turnable ladder taste also, dampness removing reduces phlegm on the basis of replenishing QI to invigorate the spleen again; The stomach function regulating circulation of qi promoting removes moistening dryness for relaxing bowels when expanding, eliminating phlegm and relaxing heart removing food stagnancy.
Through research to non-alcohol fatty liver; Think that its pathogeny is because the long-term thick rich food of height of taking in; Gather and then cause the QI and blood retardance and cause in the body phlegm-damp, even the stagnation of QI is wetly accumulate, with the passing of time heat-transformation, liver-yin are impaired, the temper diminuendo is the card of vital QI being weakened and pathogen being violent.Because the hepatocyte of fatty liver is pressed by the shared sinus hepaticus of fat drop, can make hepatocyte impaired, ALT, AST, γ-GT rising shows diseases such as liver pain, greasy fur on tongue be thick, weak.The disease that these symptom Chinese medical discriminations are stagnation of QI due to depression of the liver, stagnation of blood stasis, phlegm-damp mutual resistance, wet and accumulate interior.Aspect treatment, need to adopt the method for depressed liver-energy dispersing and QI regulating, clearing away heat and eliminating dampness, expectorant, repercussive, the fat that disappears, removing food stagnancy, to remove gathering of fat; The method that is aided with the nourishing the liver spleen invigorating simultaneously is with the liver protecting, protection taste, protects whole healthyly, and removing the relative excess just can not hindered, and tonify deficiency can not protect heresy, so just can reach both to have treated fatty liver, again the purpose of liver injury not.Therefore aspect the medication of consideration prescription; We are on differential diagnosis of diseases and the dialectical basis that combines; According to the principle of motherland's medical science " determination of cause of disease according to differentiation of symptoms and signs, examine because of opinion and control ", and with reference in recent years clinicist's experience be developed into the Chinese medicine composition of the treatment non-alcohol fatty liver of the soothing the liver fat that disappears, heat clearing away eliminate indigestion, promoting flow of QI and blood, expectorant removing dampness.
The Chinese medicine of treatment non-alcohol fatty liver provided by the present invention can have curative effect preferably when comprising the following component of parts by weights meter: Radix Bupleuri 5-20, Radix Glycyrrhizae 4-12, Rhizoma Polygoni Cuspidati 15-45 ﹑ Radix Codonopsis 5-10 ﹑ Fructus Crataegi 10-30 ﹑ Rhizoma Alismatis 8-16 ﹑ Radix Salviae Miltiorrhizae 15-35 ﹑ Rhizoma Atractylodis Macrocephalae 5-10 ﹑ Poria 10-30 ﹑ Semen Cassiae 5-25 ﹑ Petiolus nelumbinis 10-35 ﹑ Rhizoma Acori Graminei 6-12.
The Chinese medicine that the present invention treats non-alcohol fatty liver preferably includes the following component of parts by weights meter: Radix Bupleuri 10-15 ﹑ Radix Glycyrrhizae 6-10 ﹑ Rhizoma Polygoni Cuspidati 20-40 ﹑ Radix Codonopsis 6-9 ﹑ Fructus Crataegi 15-25 ﹑ Rhizoma Alismatis 9-15 ﹑ Radix Salviae Miltiorrhizae 20-30 ﹑ Rhizoma Atractylodis Macrocephalae 6-9 ﹑ Poria 10-30 ﹑ Semen Cassiae 10-20 ﹑ Petiolus nelumbinis 15-30 ﹑ Rhizoma Acori Graminei 6-12.
The present invention treats the optimum weight of the Chinese medicine of non-alcohol fatty liver and divides the component of meter to be: the Radix Bupleuri 10 ﹑ Radix Glycyrrhizaes 6 ﹑ Rhizoma Polygoni Cuspidati 20 ﹑ Radix Codonopsis 9 ﹑ Fructus Crataegis 25 ﹑ Rhizoma Alismatis 15 ﹑ Radix Salviae Miltiorrhizaes 20 ﹑ Rhizoma Atractylodis Macrocephalaes 9 ﹑ Poria 30 ﹑ Semen Cassiaes 10 ﹑ Petiolus nelumbiniss 15 ﹑ Rhizoma Acori Graminei 6.
Each component is pressed said ratio with each component decocte with water three times, and each amount of water was not advisable to have powder, merged three times and filtrated and filter, and was divided into three equal parts after must filtrating, and took in early, middle and late three times.The treatment non-alcohol fatty liver, 20 days is a course of treatment, five days at interval each course of treatment, takes three courses of treatment of the present invention continuously; The treatment hyperlipidemia, 15 days is a course of treatment, three days at interval each course of treatment, takes three courses of treatment of the present invention continuously.
The present invention selects for use Radix Bupleuri, Radix Salviae Miltiorrhizae, Radix Codonopsis, Rhizoma Alismatis, the Rhizoma Atractylodis Macrocephalae, Poria, Rhizoma Polygoni Cuspidati, Semen Cassiae, Fructus Crataegi, Rhizoma Acori Graminei, Petiolus nelumbinis, Radix Glycyrrhizae to make up, and the kind bar of Radix Bupleuri property reaches irritability, dispersing the stagnated live-QI to relieve the stagnation of QI, the gas of the clear sun of ability elevate a turnable ladder taste; Radix Salviae Miltiorrhizae function promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing; The Rhizoma Polygoni Cuspidati bitter cold has the power of heat-clearing and dampness-resolving, and the merit of feasible promoting blood circulation to remove blood stasis pain relieving also can purging heat to relax the bowels; Semen Cassiae function loosening bowel to relieve constipation; The Rhizoma Alismatis removing water retention by purgation is wet, the row phlegm retention; Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, dampness diuretic; Poria property is sweet, flat, light, both can be eliminating evil, can set upright again, and diuretic and do not hinder healthy energy, kind can oozing sluices wetly, and making does not wetly have institute and gathers, the expectorant life of having no way of; Radix Codonopsis is returned spleen, lung meridian, and function spleen reinforcing lung qi share more beneficial air making-up and spleen enlivening dehumidifying with the Rhizoma Atractylodis Macrocephalae, Poria; The Rhizoma Acori Graminei pungent drugs can disperse and bitter drugs can descend has the logical effect of temperature concurrently, and fragrance is walked to scurry, and kind removing dampness is turbid, the stomach of being amusing, circulation of qi promoting stagnate, relieving distension is full, ourly wards off dirty merit to control the foul heresy of phlegm-damp with its removing dampness eliminating phlegm; Fructus Crataegi returns spleen, stomach, Liver Channel, and tepor is not hot, kind promoting digestion and removing stagnation, regulating qi to disperse stagnation; The Petiolus nelumbinis bitter in the mouth, property is flat, and the chest stuffiness relieving stomach function regulating of can ventilating cures mainly diseases caused by exogenous pathogenic factor heat-damp in summer, uncomfortable in chest not smooth; The invigorating the spleen and benefiting QI of Radix Glycyrrhizae function, coordinating the actions of various ingredients in a prescription.
Each efficacy of drugs produces synergism, thereby can treat hyperlipidemia, non-alcohol fatty liver effectively, and Rhizoma Polygoni Cuspidati, Semen Cassiae etc. can promote intestinal peristalsis promoting, reduces exogenous cholesterol absorption; Rhizoma Alismatis can reduce the generation of synthetic cholesterol raw material S-acetyl-coenzyme-A; The Fructus Crataegi water decoction can increase cholesterol biosynthesis speed limit vigor; It is synthetic to suppress the endogenous lipid; Danshensu has the endogenous cholesterol anabolic effect of inhibition and the proteic Oxidation of lipotropism on external cell membrane, thereby cholesterol reducing prevents lipidosis; Saikoside can promote the blood cholesterol turnover, promotes the transhipment and the drainage of body lipid.The present invention is eliminating evil to develop simultaneously with setting upright; Have remarkable efficacy such as harmonizing the liver and spleen kidney, nourishing blood and promoting blood circulation blood stasis dispelling softening the hard mass, blood fat reducing detoxifcation; The patient takes the aftersensation heart, and early gas is refreshing and suitable happy, has no side effect; Be applicable to the treatment of various hyperlipidemia, non-alcohol fatty liver, treatment effective percentage and cure rate are higher.
The specific embodiment
Below in conjunction with embodiment the present invention is described further, embodiment obtains the preparation example and uses this preparation example to carry out the mode that clinical treatment observation combines.
Embodiment one
Preparation example one is used the crude drug (the individual consumption of sufferer) of following consumption proportion: Radix Bupleuri 5g ﹑ Radix Glycyrrhizae 12g ﹑ Rhizoma Polygoni Cuspidati 20g ﹑ Radix Codonopsis 9g ﹑ Fructus Crataegi 25g ﹑ Rhizoma Alismatis 15g ﹑ Radix Salviae Miltiorrhizae 20g ﹑ Rhizoma Atractylodis Macrocephalae 10g ﹑ Poria 30g ﹑ Semen Cassiae 25g ﹑ Petiolus nelumbinis 35g ﹑ Rhizoma Acori Graminei 6g.
With above-mentioned each component decocte with water three times, each amount of water was not advisable to have powder, merged filtrating three times, crossed to filter filtrating 600ml, divided morning, in, lately give the sufferer individuality three times and take, take 200ml at every turn.The treatment non-alcohol fatty liver, 20 days is a course of treatment, five days at interval each course of treatment, takes three courses of treatment of the present invention continuously; The treatment hyperlipidemia, 15 days is a course of treatment, three days at interval each course of treatment, takes three courses of treatment of the present invention continuously.
Use the clinical observation of preparation example one treatment hyperlipidemia, non-alcohol fatty liver.
1, case is selected: clinically select 152 routine patients at random, male patient's 89 examples wherein, female patient 63 examples.73 examples of suffering from non-alcohol fatty liver among the male patient suffer from 36 examples of hyperlipidemia; 43 examples of suffering from non-alcohol fatty liver in the female patient suffer from 23 examples of hyperlipidemia.
2, diagnostic criteria:
(1) non-alcohol fatty liver patient clinical symptoms: inappetence, weak, detest oil, feel sick, vomiting, abdominal distention, dull pain in liver, epigastric discomfort, dizziness, sialorrhea, pulse is slow, blood pressure reduction etc.;
(2) B ultrasonic detects: liver increases, and first half luminous point enhancing, intensive is evenly distributed, and blood vessel moves towards disorderly in the liver, attenuates, and liver edge circle is blunt, and spleen increases, and two terminal circle is blunt, and echo is spared;
(3) lipids detection; Exceed following indication range for unusual: T-CHOL (TC) 3.12～6.0mmol/L; Triglyceride (TG) 0.4-1.8mmol/L; High density ester gp cholesterol (HDL-TC) 0.90-1.95mmol/L, low-density ester gp cholesterol (LDL-TC) 2.0-4.1mmoll/L;
(4) liver function conventional sense exceeds following indication range for unusual: glutamate pyruvate transaminase (ALT) 0-50U/L, glutamic oxaloacetic transaminase, GOT (AST) 0-40U/L, gamma glutamyl transpeptidase (0-40U/L of γ-GT), alkali phosphatase (AKP) 30-140U/L.
3, curative effect is judged:
Produce effects: clinical symptom disappearance, blood drawing are chemically examined liver function, blood lipids index is normal, and B ultrasonic diagnosis liver and spleen retraction is normal or liver is big slightly;
Take a turn for the better: clinical symptoms takes a turn for the better, and blood drawing chemical examination liver function, blood fat are near normal, and B ultrasonic diagnosis liver spleen is big slightly;
Invalid: clinical symptoms does not take a turn for the better, and liver function is chemically examined in blood drawing, blood fat is still undesired, and B ultrasonic diagnosis liver is splenauxe still obvious.
4, therapeutic effect: use three courses of treatment of preparation example one treatment, 152 examples, produce effects 56 examples as a result, 96 examples that take a turn for the better, invalid 0 example, obvious effective rate is 36.8%, and improvement rate is 63.2%, and inefficiency is 0, and total effective rate is 100%.
Embodiment two
Preparation example two is used the crude drug (the individual consumption of sufferer) of following consumption proportion: Radix Bupleuri 20g ﹑ Radix Glycyrrhizae 4g ﹑ Rhizoma Polygoni Cuspidati 15g ﹑ Radix Codonopsis 10g ﹑ Fructus Crataegi 30g ﹑ Rhizoma Alismatis 8g ﹑ Radix Salviae Miltiorrhizae 35g ﹑ Rhizoma Atractylodis Macrocephalae 5g ﹑ Poria 30g ﹑ Semen Cassiae 5g ﹑ Petiolus nelumbinis 10g ﹑ Rhizoma Acori Graminei 12g.
Use with prepare example one identical method to obtain filtrating and give the sufferer individuality to take same dose, use and prepare routine one identical Therapeutic Method and treat hyperlipidemia, non-alcohol fatty liver.
Use the clinical observation of preparation example two treatment hyperlipidemia, non-alcohol fatty liver.
1, case is selected: clinically select 87 routine patients at random, male patient's 50 examples wherein, female patient 37 examples.42 examples of suffering from non-alcohol fatty liver among the male patient suffer from 32 examples of hyperlipidemia; 22 examples of suffering from non-alcohol fatty liver in the female patient suffer from 18 examples of hyperlipidemia.
2, diagnostic criteria: with embodiment one.
3, curative effect is judged: with embodiment one.
4, therapeutic effect: use three courses of treatment of preparation example two treatments, 87 examples, produce effects 33 examples as a result, 54 examples that take a turn for the better, invalid 0 example, obvious effective rate is 37.9%, and improvement rate is 62.1%, and inefficiency is 0, and total effective rate is 100%.Compare with embodiment one, patient's sum of embodiment two decreases, but curative effect is similar, is more or less the same in other words.
Embodiment three
Preparation example three is used the crude drug (the individual consumption of sufferer) of following consumption proportion: Radix Bupleuri 15g ﹑ Radix Glycyrrhizae 10g ﹑ Rhizoma Polygoni Cuspidati 40g ﹑ Radix Codonopsis 9g ﹑ Fructus Crataegi 25g ﹑ Rhizoma Alismatis 15g ﹑ Radix Salviae Miltiorrhizae 20g ﹑ Rhizoma Atractylodis Macrocephalae 9g ﹑ Poria 20g ﹑ Semen Cassiae 20g ﹑ Petiolus nelumbinis 30g ﹑ Rhizoma Acori Graminei 10g.
Use with prepare example one identical method to obtain filtrating and give the sufferer individuality to take same dose, use and prepare routine one identical Therapeutic Method and treat hyperlipidemia, non-alcohol fatty liver.
Use the clinical observation of preparation example three treatment hyperlipidemia, non-alcohol fatty liver.
1, case is selected: clinically select 65 routine patients at random, male patient's 38 examples wherein, female patient 27 examples.35 examples of suffering from non-alcohol fatty liver among the male patient suffer from 28 examples of hyperlipidemia; 18 examples of suffering from non-alcohol fatty liver in the female patient suffer from 16 examples of hyperlipidemia.
2, diagnostic criteria: with embodiment one.
3, curative effect is judged: with embodiment one.
4, therapeutic effect: use three courses of treatment of preparation example three treatments, 65 examples, produce effects 29 examples as a result, 36 examples that take a turn for the better, invalid 0 example, obvious effective rate is 44.6%, and improvement rate is 55.4%, and inefficiency is 0, and total effective rate is 100%.Compare with embodiment two with embodiment one, patient's sum of embodiment three is less, promotes to some extent on the curative effect, and obvious effective rate promotes bigger.
Embodiment four
Preparation example four is used the crude drug (the individual consumption of sufferer) of following consumption proportion: Radix Bupleuri 10g ﹑ Radix Glycyrrhizae 6g ﹑ Rhizoma Polygoni Cuspidati 20g ﹑ Radix Codonopsis 9g ﹑ Fructus Crataegi 25g ﹑ Rhizoma Alismatis 15g ﹑ Radix Salviae Miltiorrhizae 20g ﹑ Rhizoma Atractylodis Macrocephalae 9g ﹑ Poria 30g ﹑ Semen Cassiae 10g ﹑ Petiolus nelumbinis 15g ﹑ Rhizoma Acori Graminei 6g.
Use with prepare example one identical method to obtain filtrating and give the sufferer individuality to take same dose, use and prepare routine one identical Therapeutic Method and treat hyperlipidemia, non-alcohol fatty liver.
Use the clinical observation of preparation example four treatment hyperlipidemia, non-alcohol fatty liver.
1, case is selected: clinically select 78 routine patients at random, male patient's 45 examples wherein, female patient 33 examples.39 examples of suffering from non-alcohol fatty liver among the male patient suffer from 26 examples of hyperlipidemia; 25 examples of suffering from non-alcohol fatty liver in the female patient suffer from 19 examples of hyperlipidemia.
2, diagnostic criteria: with embodiment one.
3, curative effect is judged: with embodiment one.
4, therapeutic effect: use the present invention to treat three courses of treatment of 78 examples, produce effects 36 examples as a result, 42 examples that take a turn for the better, invalid 0 example, obvious effective rate is 46%, and improvement rate is 54%, and inefficiency is 0, and total effective rate is 100%.Compare with embodiment one, the sufferer sum of embodiment four is less, and it is bigger that curative effect strengthens amplitude; Compare with embodiment two, patient's sum of embodiment four is less slightly, and curative effect is promoted by a relatively large margin; Compare with embodiment three, patient's sum of embodiment four is slightly many, and curative effect promotes slightly.
Claims (3)
1. a Chinese medicine of treating non-alcohol fatty liver is characterized in that being made up of the following component of parts by weights meter: Radix Bupleuri 5-20, Radix Glycyrrhizae 4-12, Rhizoma Polygoni Cuspidati 15-45 ﹑ Radix Codonopsis 5-10 ﹑ Fructus Crataegi 10-30 ﹑ Rhizoma Alismatis 8-16 ﹑ Radix Salviae Miltiorrhizae 15-35 ﹑ Rhizoma Atractylodis Macrocephalae 5-10 ﹑ Poria 10-30 ﹑ Semen Cassiae 5-25 ﹑ Petiolus nelumbinis 10-35 ﹑ Rhizoma Acori Graminei 6-12.
2. the Chinese medicine of treatment non-alcohol fatty liver according to claim 1 is characterized in that being made up of the following component of parts by weights meter: Radix Bupleuri 10-15 ﹑ Radix Glycyrrhizae 6-10 ﹑ Rhizoma Polygoni Cuspidati 20-40 ﹑ Radix Codonopsis 6-9 ﹑ Fructus Crataegi 15-25 ﹑ Rhizoma Alismatis 9-15 ﹑ Radix Salviae Miltiorrhizae 20-30 ﹑ Rhizoma Atractylodis Macrocephalae 6-9 ﹑ Poria 10-30 ﹑ Semen Cassiae 10-20 ﹑ Petiolus nelumbinis 15-30 ﹑ Rhizoma Acori Graminei 6-12.
3. the Chinese medicine of treatment non-alcohol fatty liver according to claim 2 is characterized in that being made up of the following component of parts by weights meter: the Radix Bupleuri 10 ﹑ Radix Glycyrrhizaes 6 ﹑ Rhizoma Polygoni Cuspidati 20 ﹑ Radix Codonopsis 9 ﹑ Fructus Crataegis 25 ﹑ Rhizoma Alismatis 15 ﹑ Radix Salviae Miltiorrhizaes 20 ﹑ Rhizoma Atractylodis Macrocephalaes 9 ﹑ Poria 30 ﹑ Semen Cassiaes 10 ﹑ Petiolus nelumbiniss 15 ﹑ Rhizoma Acori Graminei 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101554576A CN102198203B (en) | 2011-06-10 | 2011-06-10 | Traditional Chinese medicine for treating nonalcoholic fatty liver diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101554576A CN102198203B (en) | 2011-06-10 | 2011-06-10 | Traditional Chinese medicine for treating nonalcoholic fatty liver diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102198203A CN102198203A (en) | 2011-09-28 |
| CN102198203B true CN102198203B (en) | 2012-07-04 |
Family
ID=44659358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101554576A Expired - Fee Related CN102198203B (en) | 2011-06-10 | 2011-06-10 | Traditional Chinese medicine for treating nonalcoholic fatty liver diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102198203B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103446361B (en) * | 2013-08-07 | 2015-08-19 | 寿光富康制药有限公司 | A kind of Chinese medicine composition for the treatment of stagnation of phlegm-damp in middle-JIAO type fatty liver |
| CN103736036A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Drug for treating nonalcoholic fatty liver disease and preparation method thereof |
| CN105560779B (en) * | 2014-10-15 | 2019-11-12 | 上海中医药大学附属龙华医院 | The compound preparation and application thereof for preventing and treating non-alcohol fatty liver |
| CN106109767A (en) * | 2016-07-13 | 2016-11-16 | 郑亮 | A kind of compound preparation preventing and treating non-alcohol fatty liver |
| CN118320043B (en) * | 2024-06-13 | 2024-08-09 | 长春中医药大学 | Spleen-strengthening, vein-relaxing and turbidity-reducing composition for treating non-alcoholic steatohepatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101401920A (en) * | 2008-11-06 | 2009-04-08 | 张晨 | Traditional Chinese medicine preparation for treating fatty liver |
-
2011
- 2011-06-10 CN CN2011101554576A patent/CN102198203B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101401920A (en) * | 2008-11-06 | 2009-04-08 | 张晨 | Traditional Chinese medicine preparation for treating fatty liver |
Non-Patent Citations (1)
| Title |
|---|
| 王俊丽.非酒精性脂肪性肝病中医药研究现状.《北京中医药》.2010,第29卷(第1期),72－75. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102198203A (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103007191B (en) | Chinese medicinal composition for treating jaundice | |
| CN102949630B (en) | Traditional Chinese medicine composition for treating abdominal distension caused by lack of gastrointestinal motility | |
| CN102198203B (en) | Traditional Chinese medicine for treating nonalcoholic fatty liver diseases | |
| CN102178903B (en) | Method for preparing traditional Chinese medicine for treating acute pancreatitis caused by overeating greasy food | |
| CN102940785B (en) | Traditional Chinese medicine composition for treating vertigo | |
| CN104288412A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN103316317A (en) | Traditional Chinese medicine composition for treating superficial gastritis | |
| CN102430105B (en) | Traditional Chinese medicine composite for treating chronic gastritis | |
| CN104162129A (en) | Traditional Chinese medicine for treating diabetic gastroparesis | |
| CN103041145B (en) | Traditional Chinese medicine composition for treating exogenous fever | |
| CN102940820B (en) | Traditional Chinese medicine composition for treating diarrhea | |
| CN102631630B (en) | Method for preparing traditional Chinese medicine (TCM) for treating intestine and stomach dyspepsia type colitis | |
| CN104324350A (en) | Traditional Chinese medicine composition for chronic colitis and preparation method of traditional Chinese medicine composition | |
| CN102940716A (en) | Traditional Chinese medicine for treatment of uterine prolapse | |
| CN102949659A (en) | Traditional Chinese medicine composition for treating hepatitis B | |
| CN102389541A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN101732694B (en) | Medicament for treating chronic diarrhea | |
| CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
| CN102961696A (en) | Chinese medicinal composition for treating diabetic nephropathy edema | |
| CN103263611A (en) | Traditional Chinese medicine composition for treating colonitis | |
| CN102764325B (en) | Chinese medicinal composition for dispelling rheumatism and relieving pain | |
| CN103100063A (en) | Traditional Chinese medicine for treating damp-heat type gallstone | |
| CN102824594B (en) | Traditional Chinese medicine for treating vital myocarditis | |
| CN102824482A (en) | Traditional Chinese medicine composition for treating icteric hepatitis | |
| CN102178883B (en) | Preparation method of traditional Chinese medicine for treating hunger type frostbite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20130610 |